First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability

Virgili, Annarosa; Borghi, Alessandro; Toni, Giulia; Minghetti, Sara; Corazza, Monica

doi:10.1111/bjd.12910

Cited by 63 publications

(72 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, in our series, mean itching and burning decreased significantly after treatment. Even though less evidently than the symptoms, VLS clinical features have been reported to improve with corticosteroid treatment as well …”

Section: Discussionmentioning

confidence: 99%

Clinical and dermoscopic changes of vulvar lichen sclerosus after topical corticosteroid treatment

Borghi

Corazza

Minghetti

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

With the aim to assess changes in both clinical and dermoscopic features of vulvar lichen sclerosus (VLS) after a treatment with topical corticosteroid, 29 VLS patients treated with mometasone furoate 0.1% ointment for 12 weeks were evaluated for symptoms, objective signs and dermoscopic variables at baseline and treatment completion. Numeric scores were assigned to each parameter. Mean itching and burning values had decreased significantly at the 12‐week control visit compared with baseline, as well as values referring to pallor, hyperkeratosis and purpuric lesions. Among the dermoscopic variables, the vessel score increased while the scores of patchy, structureless, whitish areas, whitish background, purpuric globules and scales decreased significantly after treatment. Scores referring to gray‐blue dots, comedo‐like openings and structures like ice slivers did not change significantly throughout the treatment. Based on these findings, dermoscopic features may change, even significantly, with topical corticosteroids and may be useful for monitoring the response to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and dermoscopic changes of vulvar lichen sclerosus after topical corticosteroid treatment

Borghi

Corazza

Minghetti

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Even though a definitive cure does not exist, the ideal treatment for VLS should aim at inducing relief of symptoms, reversing signs and preventing further anatomical changes. Topical potent and ultrapotent corticosteroids are the treatment of choice [6,7,8,9]. …”

Section: Introductionmentioning

confidence: 99%

Dermoscopic Features of Vulvar Lichen Sclerosus in the Setting of a Prospective Cohort of Patients: New Observations

et al. 2015

View full text Add to dashboard Cite

Objective: Dermoscopic features of vulvar lichen sclerosus (VLS) were investigated in order to determine both vascular and non-vascular features of this disease. Materials and Methods: Dermoscopic images of 35 patients affected with histopathologically confirmed VLS were evaluated for the presence of predefined morphological criteria. Results: On dermoscopy, VLS lesions exhibited very sparse vessels, mainly linear, without a specific arrangement. Dotted vessels were observed mostly in the early stage of the disease. Patchy, structureless areas, whitish to white-yellowish to pink-whitish in colour over a diffuse whitish background, were a distinctive and constant dermoscopic feature. Grey-blue dots, usually with a characteristic peppered arrangement, corresponding to dermal melanophages, were also frequently seen. Comedo-like openings and scales were observed, as well as peculiar structures like ice slivers, not identified by histological examination. Conclusion: Our findings show that VLS exhibits characteristic dermoscopic patterns that can aid in its clinical diagnosis.

show abstract

“…In a comparative trial, 54 women were randomized to apply either CP 0.05% ointment or MMF 0.1% ointment for 12 weeks on a tapering regimen. 4 We found that CP and MMF have similar efficacy and safety in treating active VLS, both resulting effective in improving symptoms and signs of the disease and well tolerated. Almost 90% of treated patients were considered as responders with both CP and MMF treatment, without significant differences between the 2 treatments.…”

mentioning

confidence: 67%

Efficacy and Tolerability of Mometasone Furoate in Lichen Sclerosus

Virgili

Minghetti

Corazza

et al. 2015

Journal of Lower Genital Tract Disease

View full text Add to dashboard Cite

First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability

Abstract: Clobetasol propionate and MMF appeared similarly efficacious and well tolerated for the treatment of VLS and both may represent the first-line treatment for the disease.

Cited by 63 publications

References 24 publications

Clinical and dermoscopic changes of vulvar lichen sclerosus after topical corticosteroid treatment

Clinical and dermoscopic changes of vulvar lichen sclerosus after topical corticosteroid treatment

Dermoscopic Features of Vulvar Lichen Sclerosus in the Setting of a Prospective Cohort of Patients: New Observations

Efficacy and Tolerability of Mometasone Furoate in Lichen Sclerosus

Contact Info

Product

Resources

About